Infertility, Female Clinical Trial
Official title:
Repeated Luteal Phase Ovarian Stimulation (Second Step Protocol) in Poor Responder Patients
Reduced ovarian reserve and the consequent poor ovarian response are very recurent in
infertile patients, indeed a percentage of 10%-24% of couples addressed to infertility
program may be classified as Poor Ovarian Responder (POR).
Objective: To evaluate whether the repeated luteal phase stimulation (Second Step) permits a
significantly higher number of oocytes retrieved in POR when compared to conventional
follicular stimulation.
Interventions: The follicular phase stimulation is conduced according to a standardized
Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary
gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin
(Corifollitropin alfa 150 mcg).
Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be
started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human
menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\die will be
administered when the leading follicle is ≥ 14 mm until hCG (human chorionic gonadotropin)
criteria are met. When at least two follicles had reached 17-18 mm in diameter, ovulation
will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin
(10.000 UI ) and oocyte retrieval will be performed after 35 hours.
Two or Three months after the second oocyte retrieval the Embryo transfer (ET) will be
performed after endometrial preparation with Estradiol Valerate and intramuscular
Progesterone.
Reduced ovarian reserve and the consequent poor ovarian response are very recurent in
infertile patients, indeed a percentage of 10%-24% of couples addressed to infertility
program may be classified as Poor Ovarian Responder (POR).
Poor ovarian response and reduced ovarian reserve can be caused by different factors such as
advanced female age, smoking, autoimmune diseases, aneuploidies and genetic diseases or can
be idiopathic.
An Eshre ( European Society of Human Reproduction and Embryology) consensus in 2011
established the "Bologna Criteria" that consented a standardize definition of poor ovarian
response (POR).
According with the Bologna Criteria we can diagnose a Poor Ovarian Response or an expected
Poor Ovarian Response when at least two of the following three features are present:
- Advanced maternal age (≥40 years) or any other risk factor for POR;
- A previous POR (≤3 oocytes with a conventional stimulation protocol);
- An abnormal ovarian reserve test (i.e. AFC -Antral Follicular Count- 5-7 follicles or
AMH ,0.5-1.1 ng/ml). The diagnosis and the prediction of poor ovarian response consent
the selection of the best treatment with the aim of the retrieval of an high number of
oocytes.
A lot of treatment have been proposed to optimize in vitro fertilization outcomes in POR
(high dosage of Gonadotropins; short protocol, administration of androgens or Aromatase
Inhibitors, administration of Growth Hormone and the repeated luteal phase stimulation).
The Luteal Phase Stimulation was initially proposed for fertility preservation procedures,
but in last years is used in POR patients too. The recently diffused "wave theory" support
this technique. According to the wave theory two or three cohorts of antral follicles are
recruited during the follicular and luteal phase of each ovarian cycle and in one of this
follicular wave will be selected the dominant follicle.
A trial performed in 2014 (Kuang et al, 2014) pubblished results of repeated luteal phase
stimulation (Shanghai Protocol) showing that double ovarian stimulations in the same
menstrual cycle provide more opportunities for retrieving oocytes in poor responders. More
recently another trial (Ubaldi et al 2016) did not observe significant differences in term of
number of oocytes retrieved and euploid blastocyst rate from follicular versus luteal phase
stimulation.
Objective: To evaluate whether the repeated luteal phase stimulation (Second Step) permits a
significantly higher number of oocytes retrieved in POR when compared to conventional
follicular stimulation.
Interventions: The follicular phase stimulation is conduced according to a standardized
Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary
gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin
(Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two
follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single
subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval
will be performed after 35 hours.
Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be
started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human
menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\die will be
administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least
two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single
subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval
will be performed after 35 hours.
Two or Three months after the second oocyte retrieval the Embryo transfer (ET) will be
performed after endometrial preparation with Estradiol Valerate and intramuscular
Progesterone.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05969574 -
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
|
||
Recruiting |
NCT05358483 -
PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Completed |
NCT03177538 -
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
|
Phase 4 | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Completed |
NCT04052464 -
The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
|
||
Withdrawn |
NCT04753736 -
Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC
|
N/A | |
Completed |
NCT03349905 -
Deferred Versus Fresh Embryo Transfers
|
N/A | |
Completed |
NCT05076981 -
Progesterone Levels During Ovulation and Luteal Phase
|
||
Completed |
NCT04096027 -
Cabergoline Before or After Oocyte Collection for Follicular Resolution
|
Phase 4 | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Terminated |
NCT01933633 -
Improved Fertility After Exercise in Overweight/Obese Women
|
N/A | |
Terminated |
NCT01202643 -
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
|
Phase 1/Phase 2 | |
Completed |
NCT01202656 -
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
|
Phase 1/Phase 2 | |
Completed |
NCT01408615 -
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
|
||
Enrolling by invitation |
NCT05698550 -
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
|
Phase 3 | |
Not yet recruiting |
NCT03910582 -
Personalized FET in RIF Patients With Displaced Dating
|
N/A | |
Completed |
NCT05440019 -
Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
|
||
Completed |
NCT05130125 -
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
|